CDT Stock Price, Chart, Stats & News
CDT Equity Inc. (CDT) does not currently pay a dividend.
CDT chart
Fundamentals
Gross margin | 36.48% |
Operating margin | 43.84% |
Pretax margin | 37.06% |
Net margin | 32.98% |
Effective tax rate | -2.27% |
ROA | 6.83% |
ROE | 74.52% |
D/E | 1.09x |
Interest coverage ratio | -25.86x |
CDT valuation
P/E | – |
P/S | 0.00x |
P/B | 0.00x |
P/CF | 0.00x |
P/FCF | 0.01x |
P/OCF | 0.00x |
PEG | -0.00x |
EV multiple | -13.78x |
About
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health.
Similar securities
Based on sector and market capitalization
